[quote>>This exclusion (both for the placebo and the DCVax-L group) would ensure that aggressive tumors able to evade chemoradiation would not be in the trial and perhaps make OS and PFS times longer than one would expect from a general GBM population][/quote]
NONSENSE! Witness the fact that according to the 2022 JAMA article, the mOS of the
unmethylated GBM Treatment group demonstrated no statistically significant difference
from the mOS of their matched unmethylated GBM ECAs. This strongly suggests that
the exclusion methods employed by the DCVax-L trial, though somewhat different from
the exclusion methods employed by the ECA trials, ended up with a patient population
which when challenged by GBM, was very similar in their initial vulnerability/survival capabilities
to the GBM patients of the ECAs.
It was DCVax-L that was responsible for the longer mOS of the Treatment group but that
effect was mostly expressed by the methylated GBM Treatment patients though some of the unmethylated
GBM Treatment patients also demonstrated an above normal survival benefit in that 8 of those 131
patients (6.1%)) survived more than 5 years.
Market Data 
Markets 
AI
